Pathogenetic mechanisms of immune inflammation of the vascular wall: the role of peroxisome proliferator-activated receptor alfa and gamma types and tissue factor
https://doi.org/10.18705/2311-4495-2015-0-2-3-18-22
Abstract
Peroxisome proliferator activated receptors-α и γ (PPAR) are nuclear receptors which regulate different mechanisms of immune inflammation, lipid and glucose homeostasis. One of the most important pathophysiological pathways of PPAR activation is inhibition of tissue factor expression. Tissue factor is initial link of coagulation and directly related to thrombogenesis. The main common pathogenetic mechanism of PPAR and tissue factor is signaling pathway of nuclear factor κВ (NF-κB). NF-kB is a universal transcription factor which regulate expression of genes of immune inflammation, cytokine production, cell cycle and apoptosis. The disruptions of the functioning PPAR-α and PPAR-γ lead to activation of NF-κB transcription factor which binds tissue factor gene promoter and increases its expression.
Keywords
PPAR,
тканевой фактор,
иммунное воспаление,
тромбоз,
PPAR,
tissue factor,
immune inflammation,
thrombosis
About the Authors
Zhanna Igorevna Ionova
I. P. Pavlov First St-Petersburg State Medical University
Russian Federation
Russian Federation
Olga Alexandrovna Berkovich
I. P. Pavlov First St-Petersburg State Medical University
Russian Federation
Russian Federation
Anna Alexandrovna Kostareva
Federal Almazov North-West Research Centre
Russian Federation
Russian Federation
Sofia Nikolaevna Pchelina
I. P. Pavlov First St-Petersburg State Medical University
Russian Federation
Russian Federation
Elena Gennadevna Sergeeva
I. P. Pavlov First St-Petersburg State Medical University
Russian Federation
Russian Federation
References
1. Grygiel-Gorniak В. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications a review. Nutr. J. 2014. Vol. 13, № 17.
2. Красильникова Е. Н., Красильникова Е. И., Сергеева Е. Г., Беркович О. А. Клиническое и патогенетическое значение рецепторов, активируемых пролифераторами пероксисом типа а в атерогенезе. Артериальная гипертензия 2011, N1, стр. 18-24. [Krasil'nikova E. N., Krasil'nikova E. I., Sergeeva E. G., Berkovich O.A. Klinicheskoe i patogeneticheskoe znachenie receptorov, aktiviruemyh proliferatorami peroksisom tipa а v aterogeneze. Arterial'naja gipertenzija 2011, N1, str. 18-24. In Russian]
3. Lee H. Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and IL-8 by endothelial cells. Circ. Res. 2000. Vol. 87. P. 516-521.
4. Marx N. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ. Res. 2004. Vol. 94. № 9. P. 1168-1178.
5. Mulvey C. K. Peroxisome proliferator-activated receptor-α agonism with fenofibrate does not suppress inflammatory responses to evoked endotoxemia. J. Am. Heart Assoc. 2012. Vol. 1. № 4. Article ID. e002923.
6. Usuda D., Kanda T. World J. Peroxisome proliferator-activated receptor for hypertension. Cardiol. 2014. Vol. 6, № 8. Р. 744-754.
7. Akoum S. PPAR gamma at the crossroads of health and disease: a masterchef in metabolic homeostasis.EI Akoum S. Endocrinology and metabolic syndrome 2014 3:1
8. Tedenbaum A., Fisman E. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?. Cardiovasc Diabetol. 2012. 11: 140.
9. Красильникова Е. Н., Красильникова Е. И., Сергеева Е. Г., Антонова Т. В. Клиническое и патогенетическое значение рецепторов, активируемых пролифераторами пероксисом типа γ в атерогенезе. Профилактическая и Клиническая Медицина, 2010 № 3-4 (36-37). стр. 99-107. [Krasil'nikova E. N., Krasil'nikova E. I., Sergeeva E. G., Antonova T. V. Klinicheskoe i patogeneticheskoe znachenie receptorov, aktiviruemyh proliferatorami peroksisom tipa у v aterogeneze. Profilakticheskaja i Klinicheskaja Medicina, 2010 № 3-4 (36-37). str. 99-107. In Russian]
10. Brown J. D. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. J. D. Brown, J. Plutzky. Circulation. 2007. Vol. 115. № 4. P 518-533.
11. Saha D. Tissue factor and atherothrombosis. Saha D., Sergeeva E. G., Ionova Z. I. Current Pharmaceutical Design 2015. Vol. 21. № 9. P. 1152-1157.
12. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arteriosclero. Thromb. Vasc. Biol. 2004. Vol. 24, № 6. P. 1015-1022.
13. Maly M., Vojacek J., Hrabos V. Tissue factor, tissue factor pathway inhibitor and cytoadhesive molecules in patients with an acute coronary syndrome. Physiol. Res. 2003. Vol. 52. P. 719-728.
14. Seljeflot I., Hurlen M., Hole T., Arnesen H. Soluble tissue factor as predictor of future events in patients with acute myocardial infarction. Tromb. Res. 2003. Vol. 111. P. 369-372.
15. Rickles F. R., Patierno S., Fernandez P. M. Tissue factor, thrombin, and cancerChest. 2003. Vol. 124, № 3. P. 58S-68S.
16. Steffel J., Lüscher T. F., Tanner F. C. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation. 2006. Vol. 113. № 5. P. 722-731.
17. Demetz G., Ott I. The interface between inflammation and coagulation in cardiovascular disease. International Journal of Inflammation. 2012. Article ID. 860301. 8 p.
18. Stojkovic S. IL-33 induces tissue factor in human endothelial cells impact on atherosclerotic plague thrombotic potential. Proceedings of the 18 Frontiers in Cardiovascullar Biology Congress. 2014.
19. Mackman N., Parker J. C. Tissue factor in the myocardium. Proceedings of the 18 Frontiers in Cardiovascullar Biology Congress. 2014.
20. Caterina R. Inflammation and Thrombosis. Proceedings of the ESC Congress 2015.
21. Piazza L., Ridker P. M. Is venous thromboembolism a chronic inflammatory disease? Clinical Chemistry 2015 Vol. 61. P 313-316.
22. Ridker P. M. Anti-inflammatory therapies for cardiovascular disease. European Heart Journal 2014. Vol. 35. P 1782-1791.
23. Lawrence T. The nuclear factor NF-кВ pathway in inflam mation. T. Lawrence. Harb Perspect Biol. 2009. 1 (6) Article ID: a001651.
24. Mehra V. C., Ramgolam V. S., Bender. C. J. R.ytokines and cardiovascular disease. J. Leuk. Biol. 2005. Vol. 78, № 4. P 805-818.
25. Martin D., Galisteo R., Gutkind J. S. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkB through the CBM (Carma3/Bcl10/Malt1) complex. J. of Biol. Chem. 2009. Vol. 284, № 10. P. 6038-6042.
26. Delerive P. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ. Res. 1999. Vol. 85. № 5. P. 394-402.
27. Delerive P. DNA binding-independent induction of Ikappa-В alpha gene transcription by PPAR-alpha. Mol. Endocrinol. 2002. Vol. 16. № 5. P. 1029-1039.
28. Marx N. PPAR-alpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 1999. Vol. 99. № 24. P. 3125-3131.
29. Calabroa P. Tissue factor is induced by resistin in human coronary artery endothelial cells by the NF-κB-dependent pathway. P. Calabroa, P. Cirillob, G. Limongellia [et al.]. J. Vasc. Res. 2011. Vol. 48, № 1. P. 59-66.
30. Ruf W. Phospholipid independent and dependent interactions required for tissue factor receptor and cofactor function. W. Ruf, A. Rehemtulla, J. H. Morrissey and T. S. Edgington. The Journal of Biological Chemistry. 1991. Vol. 266, № 4. P. 2158-2166.
31. Mackman N. Thromb. Haemost Regulation of the tissue factor gene. 1997. Vol. 78, № 1. P. 747-754.
Review
For citations:
Ionova Zh.I., Berkovich O.A., Kostareva A.A., Pchelina S.N., Sergeeva E.G. Pathogenetic mechanisms of immune inflammation of the vascular wall: the role of peroxisome proliferator-activated receptor alfa and gamma types and tissue factor. Translational Medicine. 2015;(2-3):18-22. (In Russ.) https://doi.org/10.18705/2311-4495-2015-0-2-3-18-22
Views:
693
Email this article 